
Sign up to save your podcasts
Or


Angela Hwang spent nearly three decades at Pfizer before joining Flagship Pioneering in 2025 as a CEO-partner and the CEO of Metaphore Biotechnologies.
In this week’s episode of "The Top Line," the former Pfizer chief commercial officer speaks with Fierce Pharma Deputy Editor Angus Liu about her transition from marketing drugs at a Big Pharma company to advancing novel technology at a young biotech startup.
Hwang discusses how her upbringing in apartheid-era South Africa—and two key lessons from her career—shaped who she is today. A longtime champion of diverse talent, she emphasizes that regardless of the broader environment or the size of an organization, it’s essential to ensure “everybody has a chance of developing in their careers and that they have a level playing field.”
To learn more about the topics in this episode:
See omnystudio.com/listener for privacy information.
By Fierce Life Sciences4.1
1212 ratings
Angela Hwang spent nearly three decades at Pfizer before joining Flagship Pioneering in 2025 as a CEO-partner and the CEO of Metaphore Biotechnologies.
In this week’s episode of "The Top Line," the former Pfizer chief commercial officer speaks with Fierce Pharma Deputy Editor Angus Liu about her transition from marketing drugs at a Big Pharma company to advancing novel technology at a young biotech startup.
Hwang discusses how her upbringing in apartheid-era South Africa—and two key lessons from her career—shaped who she is today. A longtime champion of diverse talent, she emphasizes that regardless of the broader environment or the size of an organization, it’s essential to ensure “everybody has a chance of developing in their careers and that they have a level playing field.”
To learn more about the topics in this episode:
See omnystudio.com/listener for privacy information.

3,227 Listeners

1,730 Listeners

4,386 Listeners

2,189 Listeners

398 Listeners

1,984 Listeners

350 Listeners

1,657 Listeners

173 Listeners

99 Listeners

3,986 Listeners

1,447 Listeners

338 Listeners

34 Listeners

173 Listeners